---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-165409"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2023-06-12T23:59:59+00:00"
generated_at: "2026-06-14T02:55:47.471128+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CalciMedica receives Nasdaq approval, relisting starts June 14, 2023 under CALC

## Summary
- Nasdaq approved relisting on Capital Market; trading begins June 14, 2023.
- Common stock to trade under ticker 'CALC' on Nasdaq after OTCQB trading.
- CEO cites improved liquidity, broader investor access, and support for clinical strategy.
- Company continues Phase 2 trials of Auxora for inflammatory diseases.

## SEC filing metadata
- accession: 0001193125-23-165409
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2023-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312523165409/0001193125-23-165409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312523165409/d506112d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-165409
- JSON: https://secwatch.observer/filing/0001193125-23-165409.json
- Plain text: https://secwatch.observer/filing/0001193125-23-165409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.